| abstract |
The invention is a new combined drug, particularly effective in treatingncognitive disorders specific to adults, including Alzheimer's disease,nconsisting in the combination of a cholinergic precursor (e.g. cholinenalfoscerate) and an AChE inhibitor (e.g. rivastigmine). Thencombination permits the use of lower doses of AChE inhibitors,nresulting in a reduction in the incidence of side and/or toxic effectsninduced by long-term treatment with AchE inhibitors. Furthermore, thennew drug makes higher quantities of choline, and thereforenacetylcholine, available in patients in which the inhibition of AChEnonly may not be effective due to the low neurotransmitter levels presentnin the cholinergic synapses. |